Article Text

PDF

Intravenous methylprednisolone for multiple sclerosis in relapse.
  1. M P Barnes,
  2. D E Bateman,
  3. P G Cleland,
  4. D J Dick,
  5. T J Walls,
  6. P K Newman,
  7. M Saunders,
  8. P J Tilley

    Abstract

    A randomised comparison is made between methylprednisolone, 1 g intravenously daily for 7 days, and a standard ACTH regime for the treatment of multiple sclerosis in acute relapse. It is found that methylprednisolone produces a more rapid clinical improvement than ACTH but confers no longer term benefit when the two treatments are compared at 3 months. It is proposed that intravenous methylprednisolone does have a role to play in the management of a patient with an acute relapse of multiple sclerosis.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.